Core Viewpoint - The dispute over the exclusive agency rights for the "AestheFill" product has intensified between *ST Suwu and Aimeike, following arbitration initiated by *ST Suwu's subsidiary, Datou Medical [1][2]. Group 1: Arbitration Developments - Datou Medical's request for temporary measures was approved, resulting in a temporary ban on the sale of AestheFill products by Regen in mainland China [1][3]. - The arbitration case was accepted by the Shenzhen International Arbitration Court on August 7, 2025, with Datou Medical seeking to confirm the validity of the exclusive agency agreement and claiming initial damages of 1.6 billion RMB [2]. - The arbitration decision prohibits Regen from selling AestheFill products in mainland China until the arbitration ruling is made and mandates that Regen must continue supplying the product to Datou Medical [3]. Group 2: Company Performance Impact - Both Aimeike and *ST Suwu are experiencing financial pressure, with Aimeike's revenue declining by 21.59% to 1.299 billion RMB and net profit down 29.57% to 789 million RMB in the first half of the year [4]. - *ST Suwu reported a revenue drop of 27.08% to 636 million RMB, with a net loss of 44.42 million RMB, marking a significant decline of 281.63% [4].